Searchable abstracts of presentations at key conferences in endocrinology

ea0073pep1.2 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Tildacerfont for the treatment of patients with classic congenital adrenal hyperplasia: results from a 12-week phase 2 clinical trial in adults with classic CAH

Auchus Richard , Merke Deborah , Ivy-Joan Madu , Nakhle Samer , Sarafoglou Kyriakie , Huang Michael , Moriarty David , Barnes Chris , Newfield Ron

BackgroundCongenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disorder characterized by insufficient cortisol production resulting in excess adrenocorticotropic hormone (ACTH) and adrenal androgen production. Standard-of-care therapy with glucocorticoids (GC) is suboptimal due to the difficulty of balancing control of the ACTH-driven androgen excess against the serious long-term side effects associated...